Entresto (sacubitril/valsartan) Disease area(s): Cardiovascular Manufacturer(s): Novartis 2024 Sales (USD): $7.82 billion Why it sold so well: In 2024, Novartis heart failure medication, Entresto, had remarkable sales growth, generating $7.8 billion in revenue, a 31% increase over the previous year
Morgan, the total number of GLP-1 users in the U.S
How does MIC+B12 work
Athletes should consult an endocrinologist to avoid supraphysiologic GH levels that could suppress the HPT axis
Bottom Line Semaglutide side effects are real, and it's worth going in with clear expectations
BPC-157 should not be used by people who are pregnant or breastfeeding, who have active cancer (it promotes angiogenesis), who are under 18, or who have a known allergy to it